HOME >> BIOLOGY >> NEWS
Promising results in the battle against incurable ALS muscle disease

ALS is an incurable, paralyzing neurodegenerative disorder that strikes 5 persons in every 100,000. The disease commonly affects healthy people in the most active period of their lives - without warning or previous family history. Researchers from VIB (the Flanders Interuniversity Institute for Biotechnology), under the direction of Prof. Peter Carmeliet (Catholic University of Leuven), have previously shown the importance of the VEGF protein in this disease. Now, new research from this group shows that rats with a severe form of ALS live longer following the administration of the VEGF protein as a remedy. These results open up new possibilities for the use of VEGF in the treatment of ALS.

An incurable disease of the muscles

Amyotrophic Lateral Sclerosis (ALS) can strike anyone. The Chinese leader Mao Tse Tung, Russian composer Dimitri Sjostakowitz, the legendary New York Yankee baseball player Lou Gehrig, and astro-physicist Stephen Hawkins have all been afflicted with ALS. In addition, an unusually large number of Italian professional soccer players, airline pilots, and soldiers from the Golf War have been stricken by this fatal disease. About half of them have died within three years - some even in the first year - and usually as a consequence of asphyxiation, while still 'in full possession of their faculties'.

In ALS, the patient's nerve bundles that extend to the muscles deteriorate. This causes the patient to lose control over his/her muscles, growing progressively paralyzed - but remaining (disconcertingly) fully alert mentally. The originating mechanism of this deadly disease of deterioration - which has an enormous medico-social impact - remains obscure. At present, the disease is totally untreatable - causing many ALS patients to choose euthanasia, a very controversial solution. However, previous genetic research by Peter Carmeliet and his team at the Catholic University of Leuven has led to the surprising discovery tha
'"/>

Contact: Sooike Stoops
sooike.stoops@vib.be
32-9-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
29-Nov-2004


Page: 1 2 3

Related biology news :

1. Promising protein may prevent eye damage in premature babies
2. Tailored treatments: Promising designer drug provides new insight into cancer biology
3. Promising antiobesity drug fails to produce clinically meaningful weight loss
4. Promising preclinical results with live attenuated H5N1 vaccines
5. Promising new research on hereditary diseases
6. Promising cell protein may play role in infection and dry eye
7. Promising anti-TB compound finally can be synthesized with ease
8. Promising new preventative treatment option for population of men at high risk of prostate cancer
9. Cooperative science program yields results
10. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
11. Smelling for first time results from knowing abnormalities in congenital loss of smell

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/6/2017)... , March 6, 2017 ... sales technology, today announced Predictive Sales Coach TM ... infusing actionable sales intelligence into Salesforce. This unique ... enable their sales organizations with deep knowledge of ... allow for intelligent engagement. Predictive Sales Coach extends ...
(Date:3/2/2017)... 2017 Summary This report provides ... KGaA and its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... it is exhibiting in booth 513 at the Association of Community Cancer Centers ... Hotel, March 29-31. , CANCERSCAPE unites key stakeholders from leading national organizations ...
(Date:3/29/2017)... and NEWARK, Del. , March ... privately-held regenerative medicine company, and W. L. Gore ... company, today announced a collaborative research agreement whereby the ... cell therapy delivery device technologies that provide protection from ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
(Date:3/29/2017)... 29, 2017 Research and Markets has ... and Global Markets" report to their offering. ... The study ... sequencing, biochips, RNA interference, synthetic biology tools and genome editing ... These technologies and products are analyzed to determine ...
Breaking Biology Technology:
Cached News: